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Aciclovir, as the first-line treatment, has significantly reduced mortality in children, while neurodevelopmental impairment among survivors remains high. [2] [3] [4] [5] Previous studies have shown that inadequate antiviral exposure might lead to the persistence of virus in the CSF in infants. 1 Despite wide use in paediatric clinical practice, limited data were available in children. 6 Thus, our study aims to evaluate aciclovir CSF concentration in children with viral encephalitis.
This study was conducted in our department of neurology between 2016 and 2017. Thirty-nine children receiving aciclovir as part of standard treatment for viral encephalitis (10 mg/kg q8h) were enrolled in this non-interventional study, which was designed in accordance with the legal requirements and the Declaration of Helsinki, and was approved by the institute Ethics Committee. The informed consents were obtained from the patients' parents or guardians. The CSF samples were obtained at steady-state condition using an opportunistic sampling approach after routine biochemical and microbiological tests performed as part of patient clinical care. The routine care time was adjusted to match the trough concentration (6-8 h post-dose). 7 The concentration of aciclovir in CSF was determined by using HPLC coupled with a UV detection method using 100 lL of CSF. The method was linear over the concentration range from 0.04 to 8 mg/L. The lower limit of quantification was 0.04 mg/L.
A total of 39 children were included from 2016 to 2017. The mean age and weight were 5.8 (range, 2.5 to 11.3) years and 22.4 (range, 13 to 57.5) kg, respectively. All children received standard dosing of aciclovir (10 mg/kg q8h) as part of their routine clinical care. The CSF samples were taken at a mean of 8 (range, 6 to 15) days after treatment. A total of 39 CSF samples were obtainable for analysis with a mean trough concentration of 0.24 (range, 0.11 to 0.43) mg/L. The distribution of aciclovir trough concentration is shown in Figure 1 .
As shown by our results, the aciclovir CSF trough concentation after receiving the standard dosing could not achieve the pharmacodynamic targets of herpes simplex virus (HSV; 1.0 mg/L) or varicella zoster virus (VZV; 0.45 mg/L) infection. 6, 8 The inadequate aciclovir exposure may be one of the significant causes of high mortality and poor neural outcomes among survivors of viral encephalitis. In infants with CNS HSV infection, after giving the standard dose of aciclovir, the neurodevelopment non-normalization rates at 12 months after treatment reached 71%. 3 A high dosing regimen of 20 mg/kg q8h has been suggested in neonates with CNS disease and showed reduced mortality and improved neurodevelopment. 2 Moreover, treatment with inadequate doses of aciclovir might also increase viral persistence and lead to the selection of resistant strains of virus. 9 The prevalence of aciclovirresistant HSV infection has reached 36% in transplant patients. 10 In conclusion, to our knowledge, aciclovir CSF concentration has been systematically evaluated for the first time in children suffering from viral encephalitis. The results demonstrated underdosing in most children. The standard dosage regimen of 10 mg/kg q8h was not sufficient for children with viral encephalitis caused by HSV or VZV. 
